BCL2L15

Summary

BCL2L15 (BCL2 like 15, HGNC:33624) is a protein-coding gene on chromosome 1p13.2, encoding Bcl-2-like protein 15 (Q5TBC7).

Predicted to be involved in apoptotic process and regulation of apoptotic process. Predicted to be active in cytosol and nucleus.

Source: NCBI Gene 440603 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_001010922

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33624
Approved symbol	BCL2L15
Name	BCL2 like 15
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	Bfk, FLJ22588
Ensembl gene	ENSG00000188761
Ensembl biotype	protein_coding
OMIM	619660
Entrez	440603

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 3 retained_intron, 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000369580, ENST00000393316, ENST00000393320, ENST00000471267, ENST00000486485, ENST00000488450, ENST00000650418

RefSeq mRNA: 1 — MANE Select: NM_001010922 NM_001010922

CCDS: CCDS30809

Canonical transcript exons

ENST00000393316 — 4 exons

Exon	Start	End
ENSE00001450380	113887249	113887581
ENSE00001605144	113876816	113881140
ENSE00003468260	113881773	113881997
ENSE00003646219	113886537	113886658

Expression profiles

Bgee: expression breadth ubiquitous, 176 present calls, max score 96.73.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3773 / max 165.6674, expressed in 40 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13921	0.1781	29
13920	0.1569	18
13918	0.0219	10
13919	0.0204	7

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	96.73	gold quality
rectum	UBERON:0001052	94.95	gold quality
mucosa of transverse colon	UBERON:0004991	94.75	gold quality
duodenum	UBERON:0002114	93.12	gold quality
jejunal mucosa	UBERON:0000399	92.96	gold quality
epithelial cell of pancreas	CL:0000083	91.85	silver quality
colonic mucosa	UBERON:0000317	89.61	gold quality
mucosa of sigmoid colon	UBERON:0004993	88.40	gold quality
body of pancreas	UBERON:0001150	86.74	gold quality
pancreatic ductal cell	CL:0002079	86.69	gold quality
colonic epithelium	UBERON:0000397	86.06	gold quality
bone marrow cell	CL:0002092	85.78	gold quality
transverse colon	UBERON:0001157	85.22	gold quality
small intestine	UBERON:0002108	84.57	gold quality
small intestine Peyer’s patch	UBERON:0003454	84.33	gold quality
gall bladder	UBERON:0002110	82.88	gold quality
pancreas	UBERON:0001264	82.86	gold quality
bone marrow	UBERON:0002371	82.10	gold quality
intestine	UBERON:0000160	79.37	gold quality
body of stomach	UBERON:0001161	79.33	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.11	gold quality
stomach	UBERON:0000945	77.93	gold quality
large intestine	UBERON:0000059	77.69	gold quality
islet of Langerhans	UBERON:0000006	77.68	gold quality
colon	UBERON:0001155	77.09	gold quality
tibialis anterior	UBERON:0001385	75.01	silver quality
vermiform appendix	UBERON:0001154	75.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.58	silver quality
caecum	UBERON:0001153	73.07	gold quality
jejunum	UBERON:0002115	72.70	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-111727	yes	316.20
E-ANND-3	yes	8.01
E-CURD-89	no	33.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

157 targeting BCL2L15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-106A-5P	99.90	73.94	2683

Literature-anchored findings (GeneRIF, showing 3)

• In the transition from normal tissue to tumour, pro-apoptotic Bfk isoform expression is substantially reduced in up to 80% of tumours isolated from the human gastrointestinal tract compared to tumours from outside the gastrointestinal tract. (PMID:15961081)
• KLF16 overexpression deleteriously affects the proliferation and migration of retinoblastoma by transcriptionally repressing BCL2L15. (PMID:32819608)
• YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. (PMID:34445183)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Bcl2l15	ENSMUSG00000044165
rattus_norvegicus	Bcl2l15	ENSRNOG00000037149

Protein

Protein identifiers

Bcl-2-like protein 15 — Q5TBC7 (reviewed: Q5TBC7)

Alternative names: Bcl-2 family kin

All UniProt accessions (3): Q5TBC7, I6LA81, Q53EI7

UniProt curated annotations — full annotation on UniProt →

Miscellaneous. Pro-apoptotic when overexpressed.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5TBC7-1	1	yes
Q5TBC7-2	2

RefSeq proteins (1): NP_001010922* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033543	BCL2L15	Family
IPR036834	Bcl-2-like_sf	Homologous_superfamily

UniProt features (16 total): helix 9, splice variant 2, turn 2, chain 1, sequence variant 1, strand 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7CCM	X-RAY DIFFRACTION	2.45
7CCL	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5TBC7-F1	86.02	0.78

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 63 (showing top): IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, LIN_APC_TARGETS, YOSHIMURA_MAPK8_TARGETS_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN, CHYLA_CBFA2T3_TARGETS_DN, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_C, BRUINS_UVC_RESPONSE_LATE, TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN, ANDERSEN_CHOLANGIOCARCINOMA_CLASS2, GSE13522_CTRL_VS_T_CRUZI_G_STRAIN_INF_SKIN_UP, ATF5_TARGET_GENES, CREB3L4_TARGET_GENES, DLX2_TARGET_GENES, FEV_TARGET_GENES

GO Biological Process (2): apoptotic process (GO:0006915), regulation of apoptotic process (GO:0042981)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
apoptotic process	1
regulation of programmed cell death	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

470 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BCL2L15	PHTF1	Q9UMS5	650
BCL2L15	BCL2L14	Q9BZR8	625
BCL2L15	RSBN1	Q5VWQ0	548
BCL2L15	AP4B1	Q9Y6B7	470
BCL2L15	AMELX	Q99217	470
BCL2L15	AMBN	Q9NP70	448
BCL2L15	MAGI3	Q5TCQ9	436
BCL2L15	CADM1	Q9BY67	436
BCL2L15	AIFM1	O95831	428
BCL2L15	LRFN4	Q6PJG9	422
BCL2L15	BCL2L10	Q9HD36	412
BCL2L15	BAG5	Q9UL15	394
BCL2L15	CHKA	P35790	392
BCL2L15	A0A2R8Y7X9	A0A2R8Y7X9	386
BCL2L15	CLDN4	O14493	382

IntAct

30 interactions, top by confidence:

A	B	Type	Score
BCL2L15	TEAD2	psi-mi:“MI:0915”(physical association)	0.610
TEAD2	BCL2L15	psi-mi:“MI:0915”(physical association)	0.610
MANF	BCL2L15	psi-mi:“MI:0915”(physical association)	0.590
MEOX2	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
BCL2L15	POLR2G	psi-mi:“MI:0915”(physical association)	0.560
BCL2L15	TEPSIN	psi-mi:“MI:0915”(physical association)	0.560
TCF4	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
REL	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
PAX6	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
POLR2G	BCL2L15	psi-mi:“MI:0915”(physical association)	0.560
BCL2L15	BAX	psi-mi:“MI:0915”(physical association)	0.400
BCL2L15	TCF4	psi-mi:“MI:0915”(physical association)	0.000
BCL2L15	REL	psi-mi:“MI:0915”(physical association)	0.000
BCL2L15	PAX6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): BCL2L15 (Two-hybrid), BCL2L15 (Two-hybrid), BCL2L15 (Two-hybrid), BAX (Affinity Capture-MS), BCL2L15 (Affinity Capture-MS), BCL2L15 (Two-hybrid), BCL2L15 (Two-hybrid), BCL2L15 (Two-hybrid), BCL2L15 (Two-hybrid), TCF4 (Two-hybrid), BAX (Affinity Capture-MS), BCL2L15 (Affinity Capture-MS)

ESM2 similar proteins: A8WWR3, B3M1F2, B4HJA7, B4JSL2, B4M686, B4N8G7, B4QVV3, B6EU02, F1QYC4, F5HGJ3, G5ED05, O14017, O36423, O74371, P03182, P0C6Z1, P0C736, P41879, P41957, P41958, P90859, Q01001, Q07440, Q08ED0, Q09292, Q0II48, Q10436, Q16548, Q39162, Q3C2I0, Q4E409, Q4QFY1, Q5TBC7, Q66610, Q6GZM8, Q6VZT9, Q751B5, Q75BE5, Q77PA8, Q8IMZ9

Diamond homologs: Q08ED0, Q0II48, Q5TBC7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

426 predictions. Top by Δscore:

Variant	Effect	Δscore
1:113881780:C:A	donor_gain	1.0000
1:113886541:C:CA	donor_gain	1.0000
1:113886546:A:AC	donor_gain	1.0000
1:113886580:T:TA	donor_gain	1.0000
1:113881767:ACTT:A	donor_loss	0.9900
1:113881768:CTTA:C	donor_loss	0.9900
1:113881769:TTAC:T	donor_loss	0.9900
1:113881770:TACC:T	donor_loss	0.9900
1:113881771:A:AC	donor_gain	0.9900
1:113881771:A:C	donor_loss	0.9900
1:113881771:AC:A	donor_gain	0.9900
1:113881772:C:CC	donor_gain	0.9900
1:113881772:CC:C	donor_gain	0.9900
1:113881772:CCCAA:C	donor_gain	0.9900
1:113881799:C:CA	donor_gain	0.9900
1:113881994:CTGT:C	acceptor_gain	0.9900
1:113881998:C:CC	acceptor_gain	0.9900
1:113886540:T:TA	donor_gain	0.9900
1:113886547:A:C	donor_gain	0.9900
1:113886654:CTCTC:C	acceptor_gain	0.9900
1:113886656:CTC:C	acceptor_gain	0.9900
1:113886656:CTCCT:C	acceptor_loss	0.9900
1:113886658:CCT:C	acceptor_loss	0.9900
1:113886659:C:CC	acceptor_gain	0.9900
1:113886659:CTATG:C	acceptor_loss	0.9900
1:113886660:T:C	acceptor_loss	0.9900
1:113887243:CCTTA:C	donor_loss	0.9900
1:113887245:TTA:T	donor_loss	0.9900
1:113887246:TAC:T	donor_loss	0.9900
1:113887247:A:C	donor_loss	0.9900

AlphaMissense

1072 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:113881775:A:G	W158R	0.982
1:113881775:A:T	W158R	0.982
1:113881773:C:A	W158C	0.977
1:113881773:C:G	W158C	0.977
1:113881794:G:C	F151L	0.951
1:113881794:G:T	F151L	0.951
1:113881796:A:G	F151L	0.951
1:113881774:C:G	W158S	0.947
1:113886613:C:G	R58P	0.922
1:113886616:A:T	L57H	0.921
1:113887355:A:C	F7L	0.915
1:113887355:A:T	F7L	0.915
1:113887357:A:G	F7L	0.915
1:113886616:A:G	L57P	0.908
1:113886604:C:T	G61D	0.903
1:113881907:C:G	A114P	0.900
1:113886642:A:C	F48L	0.899
1:113886642:A:T	F48L	0.899
1:113886644:A:G	F48L	0.899
1:113881909:A:T	L113Q	0.898
1:113887335:A:T	I14N	0.895
1:113881891:A:G	L119P	0.888
1:113886619:C:G	R56P	0.888
1:113881792:A:T	I152N	0.886
1:113881822:A:C	I142S	0.884
1:113887323:A:G	L18P	0.880
1:113881822:A:G	I142T	0.872
1:113881909:A:C	L113R	0.869
1:113886616:A:C	L57R	0.868
1:113881911:A:C	F112L	0.866

dbSNP variants (sampled 300 via entrez): RS1000019424 (1:113887188 G>C,T), RS1000148245 (1:113888142 G>A), RS1001745390 (1:113878879 C>T), RS1001821199 (1:113882720 C>T), RS1001874911 (1:113883092 G>C,T), RS1002483935 (1:113877248 G>A), RS1002586256 (1:113886017 G>A,C), RS1002739569 (1:113880319 G>A,C,T), RS1002793656 (1:113889092 G>A), RS1002851464 (1:113882895 G>A), RS1002942475 (1:113885792 C>T), RS1003296011 (1:113888762 C>T), RS1003757824 (1:113888312 A>G), RS1004048728 (1:113877476 C>A), RS1004136210 (1:113885794 G>A)

Disease associations

OMIM: gene MIM:619660 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001937_47	Breast cancer	2.000000e-08
GCST002876_10	Type 1 diabetes and autoimmune thyroid diseases	2.000000e-11
GCST004132_97	Crohn’s disease	4.000000e-06
GCST004866_5	Alopecia areata	7.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
methyleugenol	increases expression	1
titanium dioxide	increases expression	1
beta-lapachone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
abrine	decreases expression	1
(+)-JQ1 compound	decreases expression	1
MT19c compound	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Zoledronic Acid	increases expression	1
Air Pollutants	decreases expression	1
Allergens	increases expression	1
Dactinomycin	increases expression	1
Deferoxamine	increases expression, affects cotreatment, decreases reaction	1
Glucose	affects cotreatment, increases expression, decreases reaction	1
Melatonin	affects cotreatment, decreases reaction, increases expression	1
Quercetin	decreases expression	1
Zinc	affects cotreatment, increases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.